Risk of drug-induced congenital defects

被引:38
|
作者
De Santis, M [1 ]
Straface, G [1 ]
Carducci, B [1 ]
Cavaliere, AF [1 ]
De Santis, L [1 ]
Lucchese, A [1 ]
Merola, AM [1 ]
Caruso, A [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Inst Obstet & Gynaecol, Telefono Rosso Teratol Informat Serv, I-00168 Rome, Italy
关键词
congenital malformations; pregnancy; drug induced; teratogenicity;
D O I
10.1016/j.ejogrb.2004.04.022
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Defects attributable to drug therapy represent about 1% of congenital defects of known aetiology. This means that a precautionary attitude and correct use of drugs in fertile, and especially pregnant, women is a feasible form of prevention. Drugs currently in use with proven teratogenic effect number approximately 25, but new pharmaceutical drugs are constantly in preparation. Recognition of a drug-induced teratogenic effect is a complex procedure taking into account not only experimental animal data but also experience in humans. Considering that 40% of pregnancies are not planned, it follows that any drug with known or suspected teratogenic potential must be used only under strict medical control. Also, adequate knowledge on potential teratogenicity of a drug permits modification of therapy before conception. It goes without saying that any drug should be used during pregnancy only if it is essential, and it would be prudent to use only those where adequate information is provided and prior clinical experience is available. Teratology Information Services can assist both physicians and patients when any doubt exists. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:10 / 19
页数:10
相关论文
共 50 条
  • [1] Drug-induced congenital defects: Strategies to reduce the incidence
    De Santis M.
    Carducci B.
    Cavaliere A.F.
    De Santis L.
    Straface G.
    Caruso A.
    Drug Safety, 2001, 24 (12) : 889 - 901
  • [2] Bleeding manifestations of congenital and drug-induced P2Y12 defects
    Cattaneo, Marco
    PURINERGIC SIGNALLING, 2014, 10 (04) : 687 - 687
  • [3] Research Challenges for Drug-Induced Birth Defects
    Mitchell, A. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (01) : 26 - 28
  • [4] REVIEW OF DRUG-INDUCED LIMB DEFECTS IN MAMMALS
    SANDERS, DD
    STEPHENS, TD
    TERATOLOGY, 1991, 44 (03) : 335 - 354
  • [6] The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects
    Cattaneo, Marco
    BLOOD, 2011, 117 (07) : 2102 - 2112
  • [7] Drug-induced osteoporosis risk confirmed
    不详
    GERIATRIC NURSING, 2002, 23 (02) : 61 - 61
  • [8] Drug-induced malignant hyperthermia in facial/cranial defects
    Sozaski, Tomasz
    Szelag, Janina
    Sieja, Anna
    Szelag, Adam
    PHARMACOLOGICAL REPORTS, 2007, 59 : 64 - 64
  • [9] Managing the Risk of Drug-Induced Liver Injury
    Watkins, P. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (06) : 629 - 631
  • [10] Risk assessment of drug-induced QT prolongation
    Isbister, Geoffrey K.
    AUSTRALIAN PRESCRIBER, 2015, 38 (01) : 20 - 24